Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 8 to 10 amino acid residues in defined sequence
Reexamination Certificate
2008-06-19
2010-02-23
Audet, Maury (Department: 1654)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
8 to 10 amino acid residues in defined sequence
C514S002600, C424S001690
Reexamination Certificate
active
07666985
ABSTRACT:
HLA-A24-restricted peptides derived from WT1 which have an activity to induce CTLs in vivo, polynucleotides encoding said peptides, cancer vaccines using those peptides or polynucleotides in vivo or in vitro, or the like are provided. The cancer vaccines of the present invention may be used to treat many cancer patients.
REFERENCES:
patent: 6034235 (2000-03-01), Sugiyama et al.
patent: 7420034 (2008-09-01), Sugiyama et al.
patent: 2003/0092656 (2003-05-01), Sugiyama
patent: 2004/0097703 (2004-05-01), Sugiyama
patent: 2004/0247609 (2004-12-01), Sugiyama
patent: 2005/0002951 (2005-01-01), Sugiyama et al.
patent: 2005/0266014 (2005-12-01), Sugiyama et al.
patent: 1 103 564 (2001-05-01), None
patent: WO 00/18795 (2000-04-01), None
Oka, Yoshihiro et al., “Human Cytotoxic T-Iymphocyte responses specific for peptides of the Wild-type Wilms' tumor gene (WT1) Product”, Immunogenetics, vol. 51, No. 2, pp. 99-107, 2000.
Kubo, Ralph T. et al., “Definition of Specific Peptide Motifs for Four Major HLA—A Alleles”, The American Association of Immunologists, vol. 152, pp. 3913-3924, 1994.
Azuma, T. et al., British Journal of Haematology, vol. 116, pp. 601-603, (2002).
Ohminami, H. et al., Blood, vol. 95, No. 1, pp. 286-292, Jan. 1, 2000.
Rosenberg, S. et al., Immunity, vol. 10, pp. 281-287, Mar. 1999.
Bakker, A. et al., J. Exp. Med., vol. 179, pp. 1005-1009, Mar. 1994.
Kawakami, Y. et al., Proc. Natl. Acad. Sci. USA, vol. 91, pp. 3515-3519, Apr. 1994.
Brichard, V. et al., J. Exp. Med. vol. 178, pp. 489-495, Aug. 1993.
Fisk, B. et al., J. Exp. Med., vol. 181, pp. 2109-2117, Jun. 1995.
Tsang, K. et al., J. Natl. Cancer Inst. vol. 87, pp. 982-990, Jul. 5, 1995.
Correale, P. et al., J. Natl. Cancer Inst. vol. 89, No. 4, pp. 293-300, Feb. 19, 1997.
Melief, C. et al., Cur. Opin. Immunol., vol. 5, pp. 709-713, (1993).
Pardoll, D., Cur. Opin Immunol., vol. 5, pp. 719-725, (1993).
Nanda, N. et al., Cell, vol. 82, pp. 13-17, Jul. 14, 1995.
Melief, C. et al., Immunol. Rev., vol. 146, pp. 167-177, (1995).
Gessler, M. et al., Nature, vol. 343, pp. 774-778, Feb. 22, 1990.
Call, K. et al., Cell, vol. 60, pp. 509-520 (1990).
Oka, Y. et al., J. Immunol., vol. 164, pp. 1873-1880, (2000).
Tsuboi, A. et al., J. Clin. Immunol., vol. 20, No. 3, pp. 195-202, (2000).
The 31st Annual Meeting of the Japanese Society of Immunology, pp. 160, 2-C-W11-8P, Abstract enclosed. (2001).
Azuma, T., et al., “Identification of a Novel WT1-Derived Pepetide Which Induces Human Leucocyte Antigen-A24-Restricted Anti-Leukaemia Cytotoxic T Lymphocytes”, British Journal of Haematology, Mar. 2002, vol. 116, No. 3, pp. 601-603.
Ohminami, H., et al., “HLA Class I-Restricted Lysis of Leukemia Cells by a CD8 Cytotoxic T-Lymphocyte Clone Specific for WT1 Peptide”, Blood, Jan. 2000, vol. 95, No. 1, pp. 286-292.
U.S. Appl. No. 12/095,418, filed May 29, 2008, Nishihara et al.
U.S. Appl. No. 12/181,938, filed Jul. 29, 2008, Sugiyama et al.
Gotoh Masashi
Sugiyama Haruo
Takasu Hideo
Audet Maury
Chugai Seiyaku Kabushiki Kaisha
Dainippon Sumitomo Pharma Co. ,Ltd.
International Institute of Cancer Immunology, Inc.
Oblon, Spivak McClelland, Maier & Neustadt, L.L.P.
LandOfFree
HLA-A24-restricted cancer antigen peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with HLA-A24-restricted cancer antigen peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HLA-A24-restricted cancer antigen peptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4217683